Incretin-based therapies represent a novel treatment for T2DM, relying on the insulinotropic actions of the gut hormone GLP-1 and, most recently, on the combined action of GLP-1 and the gastric inhibitory polypeptide (GIP) hormones. This evidence concerns the gene GCG and type 2 diabetes mellitus.